Jenburkt Pharmaceuticals Ltd. (JENBURPH): Jenburkt Pharmaceuticals Share Price near 52-week low after 3.15% fall
- September 22, 2026
- Posted by: Harsh Piplani
- Category: News
Jenburkt Pharmaceuticals Share Price is under pressure today, with the stock at Rs 956 after falling 3.15% from the previous close. The move keeps the counter near its 52-week low zone, while market capitalisation stands at Rs 435.64 crore. Jenburkt Pharmaceuticals Ltd. (JENBURPH) is drawing attention in stock news because the latest price action confirms renewed weakness, but the supplied data does not establish a company-specific catalyst. For readers tracking Jenburkt Pharmaceuticals Share Price Today, the key question is whether this is only a short-term price swing or part of a broader trend. Univest’s data points to a clear decline, a modest turnover reading and a valuation profile that still needs to be weighed against healthcare peers.
That makes Jenburkt Pharmaceuticals Share Price relevant for both traders and long-term investors who follow 52-week low stocks, support levels and market update coverage. The stock’s technical posture is not being framed by a full indicator set here, but the price remains well below key moving averages and below its previous close. The result is a stock news event that invites closer fundamental analysis rather than a quick conclusion.
Jenburkt Pharmaceuticals Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 956 |
| Previous Close | Rs 987.1 |
| Today's Move | Rs -31.1 (-3.15%) |
| Open | Rs 997.7 |
| High | Rs 1,000 |
| Low | Rs 950 |
| Turnover | Rs 0.14 crore |
| Market Capitalisation | Rs 435.64 crore |
Jenburkt Pharmaceuticals Ltd. (JENBURPH) traded at Rs 956 versus the previous close of Rs 987.1, a fall of 3.15%. The stock opened at Rs 997.7, reached a high of Rs 1,000, touched a low of Rs 950.
Jenburkt Pharmaceuticals Share Price Today shows a clear gap between opening trade and closing weakness. The stock opened at Rs 997.7, touched an intraday high of Rs 1,000 and a low of Rs 950 before settling at Rs 956. That leaves it Rs 31.1 below the previous close of Rs 987.1, a decline of 3.15% on the session.
The day’s price action suggests sustained selling pressure after the open, even though the stock briefly tested Rs 1,000. Turnover stood at Rs 0.14 crore, while market capitalisation remained Rs 435.64 crore. Because the stock is trading close to its 52-week low, the move matters for anyone tracking Jenburkt Pharmaceuticals Share Price Live, Jenburkt Pharmaceuticals Share News or broader stocks in news coverage on the Indian stock market. The session confirms weakness, but the supplied data does not establish a company-specific trigger. For that reason, investors watching Jenburkt Pharmaceuticals Stock News will likely focus next on whether the price can stabilise above nearby support and whether market news shifts the short-term price action.
Jenburkt Pharmaceuticals Ltd. (JENBURPH) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 435.64 crore |
| P/E Ratio | 13.27x |
| P/B Ratio | 2.15x |
| ROE | 18.84% |
| ROCE | 25.34% |
| EPS | Rs 74.39 |
| Book Value Per Share | Rs 459.8 |
| Dividend Yield | 2.1% |
Jenburkt Pharmaceuticals Ltd. (JENBURPH) fundamental metrics show P/E 13.27x, P/B 2.15x, ROE 18.84%, ROCE 25.34%. These figures provide context only and are not a buy or sell signal.
Jenburkt Pharmaceuticals Ltd. has a market capitalisation of Rs 435.64 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 13.27x, P/B at 2.15x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 18.84% and ROCE of 25.34%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 74.39, book value per share of Rs 459.8, dividend yield of 2.1%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 28.58x, median ROE of 11.7%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 13.27x |
| Benchmark Median P/E | 28.58x |
| Benchmark Average P/E | 41.98x |
| Benchmark P/E Range | 0x to 747.32x |
| Company P/B Ratio | 2.15x |
| Benchmark Median P/B | 3x |
| Company ROE | 18.84% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 25.34% |
| Benchmark Median ROCE | 13.61% |
| Company Market Capitalisation | Rs 435.64 crore |
| Benchmark Median Market Cap | Rs 762.92 crore |
Jenburkt Pharmaceuticals Ltd. (JENBURPH) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a P/E ratio of 13.27x, which is below the benchmark median of 28.58x, a difference of -53.57%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a ROE of 18.84%, which is above the benchmark median of 11.7%, a difference of +61.03%. Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a ROCE of 25.34%, which is above the benchmark median of 13.61%, a difference of +86.19%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| SMS Lifesciences India Ltd. | HALEOSLABS | 447.49 | 28.08 | 2.06 | 10.03 | 12.6 |
| Medicamen Biotech Ltd. | MEDICAMEQ | 447.91 | 39.38 | 1.58 | 3.23 | 5.77 |
| Albert David Ltd. | ALBERTDAVD | 479.4 | 21.25 | 1.13 | -0.38 | 0.83 |
| Trident Lifeline Ltd. | TLL | 376.71 | 23.15 | 4.47 | 18.78 | 19.17 |
| Astonea Labs Ltd. | ASTONEALAB | 372.61 | 80.2 | 6.34 | 11.95 | 10.51 |
Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a P/E ratio of 13.27x compared with the displayed peer median of 28.08x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 18.84% compares with a peer median of 10.03% across the companies shown in the table. ROCE stood at 25.34% versus the displayed peer median of 10.51%, providing a capital-efficiency comparison. Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a market capitalisation of Rs 435.64 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Jenburkt Pharmaceuticals
- The stock is trading near its 52-week low, so price action is central to the current Jenburkt Pharmaceuticals Share Price story.
- Session weakness was clear at Rs 956, with the stock below the previous close and below its 50 DMA of Rs 1,032.56 and 200 DMA of Rs 1,068.02.
- Fundamentals remain notable, with P/E at 13.27, ROE at 18.84% and ROCE at 25.34%.
- The company’s market cap of Rs 435.64 crore keeps it in the small-cap bucket, where sentiment can shift quickly.
- Healthcare sector comparisons show valuation below the benchmark median, while profitability stays above it.
About Jenburkt Pharmaceuticals Ltd.
Jenburkt Pharmaceuticals Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. The supplied data positions it as a small-cap listed company with a market capitalisation of Rs 435.64 crore. Its financial profile indicates meaningful earnings per share of Rs 74.39, book value per share of Rs 459.8 and a dividend yield of 2.1%, which helps frame the company’s operating and valuation profile.
From a company overview perspective, the available data points to a business that is being tracked for its earnings quality and capital efficiency rather than for sheer size. Revenue and net-profit history in the supplied financial series shows quarterly movement across recent periods, with revenue at Rs 355.12 crore in Jun 26 and net profit at Rs 58.85 crore in the same period. Those numbers give context to Jenburkt Pharmaceuticals Share Price, especially when investors compare company financials with price behaviour near a yearly low. For stock market readers, Jenburkt Pharmaceuticals Stock News remains tied to both its operating record and how the market values that record.
Track Jenburkt Pharmaceuticals Share Price on Univest
Use Jenburkt Pharmaceuticals Ltd. (JENBURPH) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Investors can track Jenburkt Pharmaceuticals Share Price on Univest for live share price updates, fundamental ratios, shareholding pattern views, 52-week levels, market insights and stock analysis. Univest also brings together technical indicators, valuation snapshots and sector context so readers can follow Jenburkt Pharmaceuticals Share Price Today with a cleaner research view. If you are scanning Jenburkt Pharmaceuticals Share Price Live, the platform helps connect price action, fundamentals and market cap in one place without forcing a recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Jenburkt Pharmaceuticals Share Price falling today?
Ans. Jenburkt Pharmaceuticals Share Price fell 3.15% to Rs 956 from Rs 987.1. The data confirms the price event, but it does not establish a company-specific catalyst behind the move. The stock moved -3.15% during the session.
What is Jenburkt Pharmaceuticals Share Price today?
Ans. Jenburkt Pharmaceuticals Share Price today is Rs 956. It opened at Rs 997.7, moved between Rs 950 and Rs 1,000, and ended below the previous close of Rs 987.1. The stock moved -3.15% during the session.
Is Jenburkt Pharmaceuticals close to a 52-week low?
Ans. Yes, Jenburkt Pharmaceuticals Share Price is trading near its 52-week low zone. That is why the stock is drawing attention in 52 Week Low Stocks and Stocks at 52 Week Low searches.
What is Jenburkt Pharmaceuticals market cap?
Ans. Jenburkt Pharmaceuticals has a market capitalisation of Rs 435.64 crore. That places it in the small-cap category, where stock price moves can be sharper and sentiment often changes quickly. The company operates in the Healthcare sector.
What do the valuation metrics show for Jenburkt Pharmaceuticals Share Price?
Ans. Jenburkt Pharmaceuticals trades at a P/E of 13.27 and a P/B of 2.15. Those levels sit below the industry median in the supplied healthcare benchmark, which supports a lower valuation reading.
How does Jenburkt Pharmaceuticals compare with healthcare peers?
Ans. Jenburkt Pharmaceuticals Share Price sits alongside peers with higher P/E multiples such as Medicamen Biotech and Astonea Labs. Its profitability ratios are competitive, especially versus several benchmark companies. Comparable listed companies include SMS Lifesciences India Ltd., Medicamen Biotech Ltd., Albert.
Where can I track Jenburkt Pharmaceuticals Share Price and stock news?
Ans. You can track Jenburkt Pharmaceuticals Share Price on Univest for live price updates, technical indicators, fundamental ratios, shareholding pattern views and healthcare sector context in one place. The stock moved -3.15% during the session.
